Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
Nanoviricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company pioneering antiviral therapies using proprietary nanomedicine technology. This page serves as the definitive source for verified news and official updates regarding the company's innovative drug development programs.
Investors and researchers will find comprehensive coverage of NNVC's progress including clinical trial developments, regulatory milestones, and strategic partnerships. Our curated collection features press releases on lead candidate NV-387's advancement through clinical studies, updates on broad-spectrum antiviral research, and collaborations advancing nanoviricide platforms.
Key content categories include scientific breakthroughs in host-mimetic nanotechnology, FDA regulatory communications, financial reporting disclosures, and analysis of NNVC's position within the antiviral therapeutics market. All materials are sourced directly from company filings and authorized statements to ensure reliability.
Bookmark this page for streamlined access to NNVC's latest developments in nanoscale antiviral solutions. Check regularly for updates on clinical programs targeting respiratory viruses, herpes-related infections, and other viral pathogens through NNVC's novel therapeutic approach.
NanoViricides, Inc. (NYSE American: NNVC) presented updates on its COVID-19 drug development program at the Benzinga Healthcare Small Cap Conference on September 30, 2021. The company is advancing two drug candidates, NV-CoV-2 and NV-CoV-2-R, which target SARS-CoV-2 and its variants. Both candidates demonstrated superior efficacy compared to Remdesivir in animal studies, extending lifespan significantly. NV-CoV-2-R is particularly notable for blocking the virus's lifecycle through dual mechanisms. The company is preparing for clinical trials and emphasizes the potential for oral administration, particularly for pediatric use.
NanoViricides, Inc. (NNVC) announced significant advancements in its COVID-19 treatment candidate NV-CoV-2-R, which incorporates remdesivir. Data showed that encapsulated remdesivir in NV-CoV-2-R resulted in nearly double the plasma retention compared to standard formulations, enhancing antiviral efficacy. Importantly, NV-CoV-2-R exhibited lower toxicity, with only 3% weight loss in test subjects compared to 9.5% with standard remdesivir. This dual-action drug aims to develop a pan-coronavirus therapy, addressing issues with current vaccines and antibodies against evolving variants.
NanoViricides, Inc. (NNVC) announced the successful licensing of the human Coronavirus field for drug development from TheraCour Pharma, Inc. on September 8, 2021. The agreement allows NanoViricides to develop anti-coronavirus treatments, with no upfront payments required. The company is progressing its COVID-19 drug candidates, NV-CoV-2 and NV-CoV-2-R, towards clinical trials. They believe their drugs will remain effective against emerging variants, aided by a comprehensive patent strategy that offers substantial market potential. The agreement includes milestone payments and royalty agreements based on future sales.
NanoViricides, Inc. (NYSE American: NNVC) filed its quarterly report for Q3 FY2021, reporting approximately $23.23 million in current assets and $0.87 million in cash liabilities, with no debt and $31.89 million in stockholders' equity. The company aims to advance its COVID-19 drug candidates, NV-CoV-2 and NV-CoV-2-R, towards human clinical trials. Both candidates have shown substantial antiviral effects in animal models, significantly outperforming Remdesivir. The company is preparing for FDA IND submissions and has sufficient funds for initial human trials.
NanoViricides, Inc. (NNVC) announced promising results for its COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R, demonstrating significant effectiveness in preclinical animal studies. NV-CoV-2 extended the lifespan of infected rats by four times compared to remdesivir, while NV-CoV-2-R extended it by five times. Body weight loss was substantially less in treated groups. Both candidates are being prepared for a pre-IND application aimed at human clinical studies, potentially addressing the need for effective antiviral treatments as COVID-19 variants evolve.
NanoViricides, Inc. (NNVC) announced significant progress in developing its COVID-19 drug candidates, NV-CoV-2 and NV-CoV-2-R. Both candidates demonstrated strong effectiveness against two distinct coronaviruses, suggesting potential efficacy against various variants. NV-CoV-2-R combines NV-CoV-2 with remdesivir, potentially enhancing its effectiveness by protecting it from metabolism in the body. The Company is preparing to submit a pre-IND application to the FDA, paving the way for human clinical trials. These developments indicate a strong outlook for combating coronaviruses amid ongoing global challenges.
NanoViricides, Inc. (NNVC) filed its Q2 FY2021 report, announcing current assets of approximately $18.39 million against liabilities of $0.34 million. The company has no debt and stockholder's equity stands at about $27.74 million. Despite no revenues reported, NanoViricides is advancing its broad-spectrum antiviral candidates for COVID-19 towards clinical trials. The drug NV-CoV-2 aims to target all coronavirus variants, while NV-CoV-2-R combines this with remdesivir to enhance treatment efficacy. The company is preparing to submit a pre-IND application to the FDA.
NanoViricides, Inc. (NYSE American: NNVC) announced that its anti-coronavirus drug candidate, NV-CoV-2, was well tolerated in safety pharmacology studies, paving the way for human clinical trials. Conducted by a contract research organization, these studies showed no adverse effects on respiratory and cardiovascular functions in animal models. The company plans to submit a pre-IND application to the US FDA soon. As new variants of the virus emerge, the need for a broad-spectrum treatment is emphasized, underlining the potential market opportunity for NV-CoV-2.
NanoViricides, Inc. (NNVC) emphasizes the urgent need for broad-spectrum antiviral therapies to combat COVID-19, highlighting recent developments and the challenges posed by emerging virus variants. President Anil Diwan points out that current vaccines and antibody treatments may become ineffective against these variants. The company's unique nanoviricide technology aims to directly attack and disable viruses, potentially remaining effective despite mutations. Currently, NNVC is preparing for human clinical trials after completing core safety studies, positioning itself as a leader in antiviral drug development amidst the ongoing pandemic.
NanoViricides, Inc. (NYSE Amer.:NNVC) announced the appointment of Brian Zucker, CPA to its Board of Directors effective November 13, 2020. Zucker brings over 30 years of CPA experience, specializing in the securities industry, and is currently a Partner at CFO Financial Partners. His addition aims to enhance the Board's Audit, Nomination, and Compensation Committees. The company is also focused on advancing its drug candidates, including one for COVID-19, pending further regulatory developments.
